Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kudinchoside A is a triterpenoid saponin isolated from the leaves of *Ilex kudingcha*, a plant traditionally used in China to prepare Kuding tea. It is being investigated by The Third Hospital of Changsha for its potential therapeutic applications in chronic respiratory diseases, including bronchial asthma and chronic obstructive pulmonary disease (COPD). The compound exhibits potent anti-inflammatory properties, primarily through the inhibition of the NF-kappaB signaling pathway and the subsequent reduction in the production of Th2-associated pro-inflammatory cytokines such as Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13). Research indicates that kudinchoside A can effectively reduce airway hyperresponsiveness, inflammatory cell infiltration, and mucus hypersecretion in animal models of respiratory distress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on kudinchoside a.